IDEAYA Biosciences, Inc. (IDYA) Key Metrics
IDYA valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $3.17B
- Enterprise value
- $2.81B
- P/E (TTM)
- —
- Forward P/E
- 4.6
- PEG ratio
- —
- Price / sales
- 13.5 10-yr median 23.8
- Price / book
- 3.0 10-yr median 2.2
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- −0.04
IDYA key metrics, 2017–2025
Fiscal year ended December 31, 2025 · U.S. dollarsIDYA valuation Price multiples at each fiscal year-end price.
Price / sales−95.3%
14.0
2025 · hover or tap a bar for each year
20172025
Price / book+50.9%
3.0
2025 · hover or tap a bar for each year
20172025
Free cash flow yield+9.6 pts
−2.4%
2025 · hover or tap a bar for each year
20172025
IDYA returns How much profit the business earns on the capital it uses.
Return on equity+21.7 pts
−10.9%
2025 · hover or tap a bar for each year
20172025
Return on invested capital+72.2 pts
−30.9%
2025 · hover or tap a bar for each year
20172025
Return on assets+20.8 pts
−10.2%
2025 · hover or tap a bar for each year
20172025
Free cash flow margin
−33.6%
2025 · hover or tap a bar for each year
20172025
Asset turnover+2,380.9%
0.20
2025 · hover or tap a bar for each year
20172025
IDYA per-share figures Results divided by the shares outstanding at year-end.
Revenue per share+2,784.1%
$2.47
2025 · hover or tap a bar for each year
20172025
Earnings per share
−$1.28
2025 · hover or tap a bar for each year
20172025
Free cash flow per share
−$0.83
2025 · hover or tap a bar for each year
20172025
Book value per share−10.8%
$11.56
2025 · hover or tap a bar for each year
20172025
Shares outstanding+8.3%
88.5M
2025 · hover or tap a bar for each year
20172025
IDYA financial health Debt, liquidity and how easily interest is covered.
Debt / equity+50.8%
0.03
2025 · hover or tap a bar for each year
20172025
Net debt+$45.7M
−$611.5M
2025 · hover or tap a bar for each year
20172025
Current ratio−24.3%
11.34
2025 · hover or tap a bar for each year
20172025
Debt / assets+47.5%
0.03
2025 · hover or tap a bar for each year
20172025
IDYA efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding+4 days
5 days
2025 · hover or tap a bar for each year
20172025
Days payables outstanding−1,029 days
19 days
2025 · hover or tap a bar for each year
20172025
Cash conversion cycle+1,033 days
-14 days
2025 · hover or tap a bar for each year
20172025
Capex / revenue−54.0 pts
1.1%
2025 · hover or tap a bar for each year
20172025
IDYA valuation history
Fiscal year-endToday9-year median
IDYA returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
IDYA debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
IDYA price vs earnings per share
Share price at year-endEPS (right axis)
IDYA key metrics
2017–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Valuation | |||||||||
| Market capitalization | $3.06B | $2.10B | $2.05B | $753.1M | $833.4M | $346.1M | $151.8M | — | — |
| Enterprise value | $2.45B | $1.44B | $1.52B | $391.7M | $591.8M | $69.2M | $59.6M | — | — |
| Price / sales | 14.0 | 299.9 | 87.5 | 14.8 | 29.8 | 17.7 | — | — | — |
| Price / book | 3.0 | 2.0 | 3.3 | 2.2 | 2.8 | 1.7 | 1.5 | — | — |
| Price / free cash flow | — | — | — | — | — | 6.3 | — | — | — |
| Price / operating cash flow | — | — | — | — | — | 6.2 | — | — | — |
| EV / sales | 11.2 | 206.0 | 65.2 | 7.7 | 21.2 | 3.5 | — | — | — |
| EV / free cash flow | — | — | — | — | — | 1.3 | — | — | — |
| Earnings yield | −3.7% | −13.1% | −5.5% | −7.3% | −5.7% | −9.3% | −25.3% | — | — |
| Free cash flow yield | −2.4% | −12.0% | −5.7% | −12.0% | −7.0% | 15.9% | −26.8% | — | — |
| Shareholder yield (dividends + buybacks) | — | — | — | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Share price at fiscal year-end | $34.57 | $25.70 | $35.58 | $18.17 | $23.64 | $14.00 | $7.50 | — | — |
| Per share | |||||||||
| Revenue per share | $2.47 | $0.09 | $0.41 | $1.23 | $0.79 | $0.79 | $0.00 | — | — |
| Earnings per share | −$1.28 | −$3.36 | −$1.96 | −$1.32 | −$1.35 | −$1.31 | −$1.90 | — | — |
| Operating cash flow per share | −$0.80 | −$3.03 | −$2.00 | −$2.10 | −$1.58 | $2.24 | −$1.94 | — | — |
| Free cash flow per share | −$0.83 | −$3.08 | −$2.04 | −$2.19 | −$1.66 | $2.22 | −$2.01 | — | — |
| Cash per share | $7.23 | $8.28 | $9.13 | $8.80 | $7.00 | $11.47 | $4.89 | — | — |
| Book value per share | $11.56 | $12.97 | $10.80 | $8.43 | $8.55 | $8.02 | $4.96 | — | — |
| Tangible book value per share | $11.56 | $12.97 | $10.80 | $8.43 | $8.55 | $8.02 | $4.96 | — | — |
| Capex per share | $0.03 | $0.05 | $0.04 | $0.08 | $0.08 | $0.02 | $0.07 | — | — |
| Debt per share | $0.32 | $0.23 | $0.05 | $0.08 | $0.15 | $0.27 | $0.33 | — | — |
| Shares outstanding | 88.5M | 81.7M | 57.5M | 41.4M | 35.3M | 24.7M | 20.2M | — | — |
| Change in shares outstanding | +8.3% | +42.0% | +38.8% | +17.6% | +42.6% | +22.2% | — | — | — |
| Returns & profitability | |||||||||
| Return on equity (ROE) | −10.9% | −32.7% | −23.3% | −16.8% | −19.0% | −21.6% | −149.4% | — | — |
| Return on invested capital (ROIC) | −30.9% | −103.1% | −244.3% | — | — | — | — | — | — |
| Return on assets (ROA) | −10.2% | −31.0% | −21.8% | −14.2% | −14.0% | −15.7% | −36.7% | −60.2% | −67.9% |
| Return on tangible assets | −10.2% | −24.4% | −17.4% | −14.1% | −12.5% | −10.8% | −34.0% | −35.6% | −67.9% |
| Free cash flow margin | −33.6% | — | −502.9% | −177.9% | −209.1% | 281.3% | — | — | — |
| Financial health | |||||||||
| Total debt | $27.9M | $19.2M | $2.9M | $3.5M | $5.2M | $6.7M | $6.8M | $0 | $3.2M |
| Cash & short-term investments | $639.4M | $676.3M | $525.1M | $364.8M | $246.8M | $283.6M | $99.0M | $90.0M | $13.2M |
| Net debt | −$611.5M | −$657.1M | −$522.2M | −$361.3M | −$241.6M | −$276.9M | −$92.2M | −$90.0M | −$9.9M |
| Debt / equity | 0.03 | 0.02 | 0.00 | 0.01 | 0.02 | 0.03 | 0.07 | — | — |
| Debt / assets | 0.03 | 0.02 | 0.00 | 0.01 | 0.01 | 0.02 | 0.06 | 0.00 | 0.18 |
| Current ratio | 11.34 | 14.97 | 19.65 | 11.68 | 5.56 | 7.47 | 14.65 | 16.75 | 5.58 |
| Quick ratio | 11.34 | 14.97 | 0.00 | 11.94 | 8.24 | 7.47 | 14.65 | 16.75 | 5.58 |
| Interest coverage | — | — | -6.3 | -16.2 | -99.3 | -41.6 | — | — | — |
| Working capital | $607.9M | $643.6M | $505.5M | $338.7M | $205.8M | $250.0M | $94.7M | $85.3M | $11.1M |
| Invested capital | $411.5M | $402.0M | $98.8M | −$11.9M | $59.9M | −$78.6M | $8.2M | −$138.9M | −$25.7M |
| Tangible asset value | $1.02B | $1.06B | $621.1M | $349.5M | $301.5M | $198.3M | $100.4M | −$48.9M | −$15.7M |
| Net current asset value | $580.3M | $624.8M | $504.4M | $331.9M | $171.2M | $188.6M | $89.1M | −$54.8M | −$19.6M |
| Graham net-net per share | $6.30 | $7.49 | $13.27 | $7.78 | $3.04 | $7.48 | $4.27 | — | — |
| Capital allocation | |||||||||
| Dividends paid | — | — | — | — | — | — | — | $0 | $0 |
| Share buybacks (net) | — | — | — | $0 | $0 | $0 | $0 | $0 | $0 |
| Dividends + buybacks / free cash flow | — | — | — | — | — | 0.0% | — | — | — |
| Capex / revenue | 1.1% | 55.1% | 10.1% | 6.8% | 9.5% | 2.5% | — | — | — |
| Capex / operating cash flow | — | — | — | — | — | 0.9% | — | — | — |
| Capex / depreciation | 0.52 | 1.01 | 0.59 | 1.64 | 1.53 | 0.36 | 1.09 | 1.93 | 4.49 |
| Stock-based compensation / revenue | 21.1% | 496.4% | 79.1% | 22.8% | 29.5% | 18.5% | — | — | — |
| R&D / revenue | 143.9% | 4,209.6% | 553.8% | 175.8% | 208.1% | 203.2% | — | — | — |
| SG&A / revenue | 29.0% | 561.5% | 121.0% | 46.9% | 71.8% | 77.7% | — | — | — |
| Efficiency | |||||||||
| Days sales outstanding | 5.0 | 0.5 | 1.8 | 4.7 | 19.5 | 35.1 | — | — | — |
| Days of inventory on hand | — | — | 23,873.3 | -11,258.4 | -25,664.9 | — | — | — | — |
| Days payables outstanding | 19.1 | 1,048.1 | 495.3 | 554.2 | 323.0 | 7.6 | 311.6 | 428.2 | 618.0 |
| Cash conversion cycle (days) | -14.2 | -1,047.6 | 23,379.8 | -11,807.8 | -25,968.4 | 27.4 | — | — | — |
| Receivables turnover | 73.20 | 666.67 | 204.24 | 77.52 | 18.75 | 10.41 | — | — | — |
| Payables turnover | 19.07 | 0.35 | 0.74 | 0.66 | 1.13 | 47.77 | 1.17 | 0.85 | 0.59 |
| Inventory turnover | — | — | 0.02 | — | — | — | — | — | — |
| Asset turnover | 0.20 | 0.01 | 0.05 | 0.13 | 0.08 | 0.10 | 0.00 | 0.00 | 0.00 |
| Average receivables | $3.0M | $10,500 | $114,500 | $657,000 | $1.5M | $1.9M | — | — | — |
| Average payables | $16.5M | $11.0M | $5.4M | $3.2M | $1.5M | $831,000 | $1.1M | $1.0M | $662,000 |
| Average inventory | — | — | $262.1M | −$64.8M | −$121.3M | — | — | $0 | $0 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from IDYA's annual financial statements (latest annual report filed February 17, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
IDYA valuation and financial ratios
IDEAYA Biosciences earned a return on equity of −10.9% and a return on invested capital of −30.9% in fiscal 2025. It ended the year with $27.9 million of debt and $639.4 million in cash and short-term investments, a net cash position of $611.5 million.
See the IDYA income statement, the IDYA chart for price history, or the IDYA stock overview for the latest quote and news.
IDYA key metrics FAQ
What is IDEAYA Biosciences's return on equity?
IDEAYA Biosciences's return on equity (ROE) was −10.9% in fiscal 2025: net income of -$113.7 million on average shareholders' equity of $1.0 billion.
What is IDEAYA Biosciences's ROIC?
IDEAYA Biosciences's return on invested capital was −30.9% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does IDEAYA Biosciences have?
IDEAYA Biosciences had total debt of $27.9 million at the end of fiscal 2025, a debt-to-equity ratio of 0.03 and more cash than debt.
What is IDEAYA Biosciences's free cash flow yield?
IDEAYA Biosciences generated -$73.5 million of free cash flow in fiscal 2025, a free cash flow yield of −2.4% on its market value at year-end ($3.1 billion).
What is IDEAYA Biosciences's current ratio?
IDEAYA Biosciences's current ratio was 11.34 at the end of fiscal 2025: current assets were 11.34 times current liabilities.